Helene Doubre
Suresnes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
Journal: JAMA oncology
Published: May 29, 2025
Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study).
Journal: Lung Cancer (Auckland, N.Z.)
Published: April 22, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
Journal: Clinical lung cancer
Published: April 21, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.
Journal: Targeted oncology
Published: February 03, 2025
Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study: comment from Doubre et al.
Journal: Journal of thrombosis and haemostasis : JTH
Published: December 24, 2024
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).
Journal: Clinical lung cancer
Published: November 17, 2024
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 05, 2024
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Journal: Targeted oncology
Published: October 21, 2023
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: August 03, 2023
Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival.
Journal: Research and practice in thrombosis and haemostasis
Published: July 17, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
Journal: Journal of cancer research and clinical oncology
Published: May 04, 2023
Last Updated: 09/26/2026